Supplementary Figure Legends
Table 1. Univariate analysis of phosphoprotein markers used in the study. Cutpoints for survival were selected using Xtile (see materials and methods) and minimum p-values corrected to minimise Type I error. Only variables with p<0.05 after Monte-Carlo simulation were considered significant.
Figure 1. Phosphoprotein expression of the five genetic pathway markers between histological subtypes in cohort 1 (p-values; Kruskal-Wallis test).
Figure 2. Unsupervised clustering of the five genetic pathway markers in cohort 2 reveals two main clusters (A), which do not differ with respect to prognosis. While patients with cluster 1 tumours have a worse outcome when treated with taxanes (log-rank p=0.031), this is not significant in multivariate analysis.
Figure 3. Unsupervised cluster analysis of cohort 1 tumours shows two main clusters with similar profiles of expression as in cohort 2.
Figure 4. Schematic of the pathways analysed in this study.
Figure 5. Expression of phosphoprotein markers according to histological subtype demostrates heterogeneity. (cohort 2).
Figure 6. K-means clustering of phosphoprotein data (cohort 1 shown here) produces 4 distinct phosphoprotein clusters (A) with different profiles of pathway alteration (B). (C) Overall survival according to phosphoprotein cluster show no differences in prognosis according to phosphoprotein cluster in this cohort of patients.
Cohort 1 Cohort 2
Target Minimum p-value
(corrected)
Monte-Carlo p-value HR (95% CI) Minimum p-value (corrected)
Monte-Carlo p-value
HR (95% CI)
pAKT (Ser 473) 0.220 0.680 N/A 0.382 0.480 N/A
pERK (Thr202/204) 0.082 0.550 N/A 0.660 0.680 N/A
pER (Ser118) 0.575 0.800 N/A 0.138 0.270 N/A
pCatenin (Ser33/37/41)
0.585 0.820 N/A 0.150 0.350 N/A
pSTAT3 (Ser727) 0.481 0.850 N/A 0.499 0.760 N/A
pNFB (Ser529) 0.316 0.710 N/A 0.595 0.730 N/A
pRB (Ser807/811) 0.341 0.740 N/A 0.610 0.620 N/A
pH2AX (Ser139) 0.328 0.690 N/A 0.030 0.050 1.47 (1.14,1.88)
pBRCA1 (Ser1524) 0.005 0.270 N/A 0.021 0.040 1.47 (1.17, 1.86)
p-p53 (Ser15) 0.369 0.640 N/A 0.550 0.580 N/A
Ki67 0.009 0.370 N/A 0.510 0.390 N/A
pHH3 0.035 0.390 N/A 0.050 0.040 1.47 (1.17, 1.80)
Caspase 3 0.132 0.550 N/A 0.614 0.570 N/A
Supplementary Table 1
Supplementary Figure 1
p=0.133 p=0.003 p=0.001
p=0.145 p=0.157
Supplementary Figure 2
Cluster 1 Cluster 2
A
B
p=0.436 p=0.482 p=0.031
Cluster 1 Cluster 2
Supplementary Figure 3
JAKJAK
TNFRTNFR
RTKRTKCadherinCadherin
RAS
RAF
MEK
ERK
PI3K
PIP2PIP3
AKT
STAT3
-Catenin
ER
NFB p50/52
p65/RelA
IKKIKK
IKK
p53
BRCA1
Histone H2A.X
Supplementary Figure 4
P
P
P
P
P
P
P
P
P
Supplementary Figure 5
Serous EndometrioidMixed CCMuc Other
Supplementary Figure 6
Cluster 1Cluster 2Cluster 3Cluster 4
A
B C
Top Related